Isomorphic Labs Secures $2.1 Billion Series B for AI Drug Discovery

13 articles · Updated · Endpoints News · May 12

$2.1 billion in Series B funding gives Isomorphic Labs one of the largest recent war chests in AI-driven drug discovery.
The company said the round closed Tuesday, reinforcing its position as a bellwether for using artificial intelligence to identify and develop new medicines.
The raise highlights investor appetite for platforms that promise to speed drug discovery, even as privately held AI biotech companies face pressure to prove commercial results.

Isomorphic Labs has billions to design drugs, but can its AI conquer the unpredictability of human biology in clinical trials?

With its mission to 'solve all disease,' will AI-designed drugs break the high-cost paradigm or become treatments only the wealthy can afford?

As AI becomes the drug designer, how will regulators and doctors learn to trust the decisions of these 'black box' models?